首页> 外文期刊>Seminars in Thrombosis and Hemostasis >Prohemostatic interventions in Trauma: Resuscitation-associated coagulopathy, acute traumatic coagulopathy, hemostatic resuscitation, and other hemostatic interventions
【24h】

Prohemostatic interventions in Trauma: Resuscitation-associated coagulopathy, acute traumatic coagulopathy, hemostatic resuscitation, and other hemostatic interventions

机译:创伤中的止血干预:复苏相关性凝血病,急性创伤性凝血病,止血复苏和其他止血干预

获取原文
获取原文并翻译 | 示例
       

摘要

Trauma is the most common cause of death in the young and hemorrhage is the most important cause of death in patients with trauma. Recently redefined pathways of inflammation and coagulation, together with hypothermia and acidosis contribute to trauma-associated coagulopathy and aggravation of bleeding. Pharmacological prohemostatic agents may be useful to (partly) correct the coagulopathy in trauma patients and may serve as useful adjunctive treatment options in patients with severe blood loss after trauma. Recombinant factor VIIa, fibrinogen and prothrombin complex concentrates, and antifibrinolytic agents have been evaluated in clinical trials. These interventions show promising effects but their efficacy in reducing clinically important outcome parameters need to be confirmed in clinical studies.
机译:创伤是年轻人中最常见的死亡原因,而出血是创伤患者中最重要的死亡原因。最近重新定义的炎症和凝血途径,以及体温过低和酸中毒,都与创伤相关的凝血病和出血加剧有关。药理止血药可用于(部分)纠正创伤患者的凝血病,并可作为创伤后严重失血患者的有用辅助治疗选择。重组因子VIIa,纤维蛋白原和凝血酶原复合物浓缩物以及抗纤维蛋白溶解剂已在临床试验中进行了评估。这些干预措施显示出令人鼓舞的效果,但是它们在降低临床重要结局参数方面的功效需要在临床研究中得到证实。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号